改良阿特金斯饮食在药物难治性癫痫患者中的安全性、疗效与耐受性:一项随机对照试验
在印度一家三级转诊中心开展的前瞻性随机对照试验,纳入160例10-55岁药物难治性癫痫患者,比较改良阿特金斯饮食(MAD)联合标准药物治疗(SDT)与单用SDT的疗效。6个月时,干预组癫痫发作频率减少>50%的比例为26.2%,对照组为2.5%(95%CI 13.5-33.9,p<0.001),生活质量改善更明显,行为评分在49例可评估患者中亦见改善。MAD是控制癫痫发作的有效方式,需进一步研究评估生物标志物及代谢组学。
要点
- MAD联合SDT较单用SDT更可能使药物难治性癫痫患者发作频率减少>50%。
- MAD组生活质量改善优于对照组,行为评分在可评估患者中亦见改善。
- 研究中1例患者出现体重下降,2例出现腹泻。
核心结论
- MAD组在癫痫发作频率减少和行为问题改善方面均优于对照组,MAD是控制癫痫发作的有效方式。
- 作者认为需要进一步研究,结合生物标志物和描述性代谢组学研究评估MAD的疗效。
研究设计与样本
- 前瞻性随机对照试验,在印度一家三级转诊中心开展。
- 纳入2015年8月至2019年4月期间门诊就诊的10-55岁药物难治性癫痫患者,每月发作>2次,尽管使用至少3种适当抗癫痫药物(ASM)达最大耐受剂量,且过去1年内未采用任何饮食疗法。
- 共筛查243例患者,随机分配160例(80例成人,80例青少年)至SDT联合MAD组(干预组)或单用SDT组(对照组)。
- 主要结局为6个月时癫痫发作频率减少>50%,次要结局包括生活质量(QOL)、行为、不良事件和退出率,采用意向性分析。
主要发现
- 6个月时,干预组癫痫发作频率减少>50%的比例为26.2%,对照组为2.5%(95%CI 13.5-33.9,p<0.001)。
- 生活质量改善评分:干预组为52.1±17.6,对照组为42.5±16.4(均数差9.6,95%CI 4.3至14.9,p<0.001)。
- 行为评分仅在49例患者中完成,研究结束时干预组为65.6±7.9,对照组为71.4±8.1(p=0.015),干预组改善。
- 1例患者出现体重下降,2例患者出现腹泻。
临床怎么用
- 原文未据此给出推荐。
局限性
- 行为评分仅在49例患者中完成。
- 作者认为需要进一步研究,结合生物标志物和描述性代谢组学研究评估MAD的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Modified Atkins diet (MAD) has emerged as an adjuvant therapy in drug-resistant epilepsy (DRE). Most studies are in children; there is limited evidence for DRE in adults. This study aimed to investigate whether MAD along with standard drug therapy (SDT) was indeed more effective than SDT alone in reducing seizure frequency and improving psychological outcomes at 6 months in adolescents and adults with DRE (nonsurgical). METHODS: A prospective randomized controlled trial was conducted at tertiary care referral center in India. Persons with DRE aged 10-55 years attending outpatient epilepsy clinics between August 2015 and April 2019, who had more than 2 seizures per month despite using at least 3 appropriate antiseizure medications (ASMs) at their maximum tolerated doses and had not been on any form of diet therapy for the past 1 year, were enrolled. Patients were assessed for the eligibility and randomly assigned to receive SDT plus MAD (intervention arm) or SDT alone (control arm). The primary outcome was >50% reduction in seizure frequency, and the secondary outcomes were quality of life (QOL), behavior, adverse events, and rate of withdrawal at 6 months. Intention-to-treat analysis was performed. RESULTS: A total of 243 patients were screened for eligibility; 160 patients (80 adults and 80 adolescents) were randomized to either the intervention or control arm. Demographic and clinical characteristics in both groups were comparable at baseline. At 6 months, >50% seizure reduction was seen in 26.2% in the intervention group vs 2.5% in the control group (95% CI 13.5-33.9; p < 0.001). Improvement in QOL was 52.1 ± 17.6 in the intervention group vs 42.5 ± 16.4 in the control group (mean difference, 9.6; 95% CI 4.3 to 14.9, p < 0.001). However, behavior scores could be performed in 49 patients, and improvement was seen in the intervention vs control group (65.6 ± 7.9 vs 71.4 ± 8.1, p = 0.015) at the end of the study. One patient had weight loss; 2 patients had diarrhea. DISCUSSION: The MAD group demonstrated improvement in all aspects (reduction in seizure frequency and behavioral problems) compared with the control group at the end of the study. MAD is an effective modality in controlling seizures; further research is required to assess its efficacy in terms of biomarkers along with descriptive metabolomics studies. TRIAL REGISTRATION INFORMATION: The clinical trial registry of India: CTRI/2015/07/006048. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that the MAD increases the probability of seizure reduction in adolescents and adults with DRE.
引用
- Manral M, Dwivedi R, Gulati S, et al. Safety, Efficacy, and Tolerability of Modified Atkins Diet in Persons With Drug-Resistant Epilepsy: A Randomized Controlled Trial. Neurology. 2023. PMID: 36599697. doi:10.1212/WNL.0000000000206776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。